Clin Oncol | Volume 7, Issue 1 | Case Report | Open Access

Tislelizumab Combined with Arotinib in the Treatment of Advanced Renal Clear Cell Carcinoma: A Case Report and Review of Literature

Zhantao Liu and Jun Zhou1,2*

1Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, China
2Institute of Oncology, Hubei University of Arts and Science, China

*Correspondance to: Jun Zhou 

Fulltext PDF

Abstract

Based upon MSKCC or IMDC, the Metastatic Renal Cancer (MRCC) prognosis model is considered to be low, intermediate, and high risk. Targeted therapy and immunotherapy play a major role in the first-line treatment of advanced renal cancer. Because of drug resistance and high treatment costs, it is necessary to explore new treatments to reduce the economic burden while prolonging the survival time of patients as long as possible.
The present case concerns a case of a 62-year-old man presenting with multiple metastases after radical left nephrectomy. The patient received first-line chemotherapy with vinorelbine combined with fluorouracil. After 4 cycles, Brain metastases decreased significantly. Nevertheless, disease progressed after 6 cycles. Tislelizumab and Anlotinib were prescribed. After 3 months, the brain metastases, both lungs and bilateral adrenal metastases reduced, and the bone metastases were stable, the condition remained stable after 15 months.
The study is the first to propose the effectiveness of vinorelbine combined with fluorouracil in treating MRCC, while proposing a new treatment model targeted in combination with PD-1, with fewer side effects and less cost. Owing to one patient was observed in this report, further exploration of the efficacy and safety of the combination regimen is needed later on.

Keywords:

Metastatic renal cell carcinoma; Tislelizumab; Arotinib

Citation:

Liu Z, Zhou J. Tislelizumab Combined with Arotinib in the Treatment of Advanced Renal Clear Cell Carcinoma: A Case Report and Review of Literature. Clin Oncol. 2022;7:1914..

Subscribe to Our Newsletter